Agents for preventing and treating hiv and other viral infections

Patent metadata

Field	Value
Publication number	US-2016122401-A1
Application number	US-201414787130-A
Country	US
Kind code	A1
Filing date	Apr 17, 2014
Priority date	Apr 30, 2013
Publication date	May 5, 2016
Grant date	—

Abstract

An agent for preventing and/or treating HIV and other viral infections. The agent in particular comprises at least one peptide, including an amino acid sequence, which is suitable for preventing fibrils associated with Alzheimer's disease, and/or homologs, fractions and parts thereof, so as to treat and/or prevent HIV and/or other viral infections.

First claim

1 . An agent, comprising at least one substance that is suitable for inhibiting the formation of amyloid fibrils, which increase the infection efficiency of a virus, or for destroying the same, so as to treat and/or prevent the particular viral infection.

2 . The agent according to claim 1 , comprising at least one substance that is suitable for inhibiting the formation of amyloid fibrils, which increase the infection efficiency of a virus, or for destroying the same, so as to treat and/or prevent a secondary disease of the particular viral infection.

3 . The agent according to claim 1 , comprising at least one substance that is suitable for inhibiting the formation of amyloid fibrils, which increase the infection efficiency of HIV, or for destroying the same, so as to treat and/or prevent an HIV infection and/or secondary diseases, such as AIDS and/or HAD.

4 . An agent according to claim 1 , comprising at least one substance that is suitable for inhibiting the formation of amyloid beta fibrils and/or SEVI fibrils, which increase the infection efficiency of a virus, such as HIV, or for destroying the same, so as to treat and/or prevent the particular viral infection and at least one secondary disease resulting therefrom, such as AIDS and/or HAD.

5 . An agent according to claim 1 , wherein at least one substance that prevents the formation of amyloid fibrils, which increase the viral infection efficiency, or destroys the same.

6 . An agent according to claim 1 , wherein at least one peptide, serving as a substance including an amino acid sequence, which is suitable for preventing and treating fibrils associated with Alzheimer's disease, and/or homologs, fractions and parts thereof, so as to treat and/or prevent HIV and/or other viral infections and secondary diseases, such as HAD, by the peptide preventing the formation of amyloid fibrils, which increase viral infection efficiency, or destroying the same.

7 . The agent according to claim 6 , wherein at least one peptide including an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and/or SEQ ID NO: 2 and/or SEQ ID NO: 3 and/or SEQ ID NO: 4 and/or SEQ ID NO: 5 and/or SEQ ID NO: 6 and/or SEQ ID NO: 7 and/or SEQ ID NO: 8 and/or SEQ ID NO: 9 and/or SEQ ID NO: 10 and/or SEQ ID NO: 11, and/or homologs, fractions and parts thereof, so as to treat and/or prevent HIV and/or other viral infections and secondary diseases, such as HAD, by the peptide preventing the formation of amyloid fibrils, which increase viral infection efficiency, or destroying the same.

8 . An agent according to claim 1 , comprising polymers of agents and/or peptides suitable for treating and/or preventing fibrils associated with Alzheimer's disease, and/or the homologs, fractions and parts thereof, so as to treat and/or prevent HIV and/or other viral infections and secondary diseases, such as HAD, by preventing the formation of amyloid fibrils, which increase viral infection efficiency, or by destroying the same.

9 . The agent according to claim 8 , wherein polymers of peptides including amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and/or SEQ ID NO: 3 and/or SEQ ID NO: 4 and/or SEQ ID NO: 5 and/or SEQ ID NO: 6 and/or SEQ ID NO: 7 and/or SEQ ID NO: 8 and/or SEQ ID NO: 9 and/or SEQ ID NO: 10 and/or SEQ ID NO: 11, and/or the homologs, fragments or parts thereof.

10 . An agent according to claim 1 , wherein at least one peptide is substantially or entirely composed of D-amino acids.

11 . An agent according to claim 1 , for simultaneously treating and/or preventing Alzheimer's disease and HIV and/or other viral infections and the secondary diseases thereof, such as HAD.

12 . An agent according to claim 1 for simultaneously treating and/or preventing Alzheimer's disease and HIV and/or other viral diseases and the secondary diseases thereof, such as HAD, having a binding affinity to associated amyloid fibrils with a dissociation constant in the range of micromolar, preferably submicromolar, particularly preferably nanomolar, most particularly preferably of a maximum of 10 picomolar, and particularly preferably up to subpicomolar.

13 . Use of an agent according to claim 1 , for therapeutically treating and/or for preventing a viral infection and/or a secondary disease thereof.

14 . Use according to claim 13 , wherein the therapeutic treatment and/or prevention of HIV and/or HAD.

15 . Use according to claim 1 , wherein the simultaneous therapeutic treatment and/or prevention of Alzheimer's disease and of HIV and/or other viral infections and at least one secondary disease, such as HAD.

16 . Use of an agent according to claim 1 , so as to at least partially prevent the increased infectivity of viruses caused by amyloid fibrils by the agent preventing the formation of the amyloid fibrils or destroying the same.

17 . Use according to claim 13 , comprising selecting a peptide according to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and/or SEQ ID NO: 11, and/or homologs, fragments or parts thereof.

18 . A microbicidal gel, comprising at least one agent according to claim 1 .

19 . The microbicidal gel according to claim 18 , for the prevention of HIV and/or other viral infections and the secondary diseases thereof, such as HAD.

20 . The microbicidal gel according to either preceding claim 18 , for use in the genital area.

21 . A tablet, comprising at least one agent according to claim 1 .

22 . The tablet according to claim 21 , for the treatment of HIV and/or other viral infections and at least one of the secondary diseases, such as HAD.

23 . An injection solution or infusion solution, comprising at least one agent according to claim 1 .

Assignees

• Forschungszentrum Juelich Gmbh
• Forschungszentrum Juelich Gmbh

Inventors

• Funke Susanne Aileen
• Willbold Dieter
• Schaal Heiner
• Widera Marek

Classifications

• A61P31/18

  for HIV · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K38/12

  Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K38/16

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title